Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis

Objective: To compare the relative efficacy of infliximab, adalimumab and golimumab through adjusted indirect treatment comparisons (ITCs). Methods: An exhaustive search was performed until October 2013. Databases consulted were MEDLINE, EMBASE, the Cochrane Library, the Centre for Reviews and Diss...

Full description

Bibliographic Details
Main Authors: M. Galván-Banqueri, M. D. Vega-Coca, M. A. Castillo-Muñoz, C. Beltrán Calvo, T. Molina López
Format: Article
Language:English
Published: Grupo Aula Médica 2015-01-01
Series:Farmacia Hospitalaria
Subjects:
Online Access:http://www.aulamedica.es/fh/pdf/8218.pdf
id doaj-329dbf46d0ae4b01aba0675da7d0878c
record_format Article
spelling doaj-329dbf46d0ae4b01aba0675da7d0878c2020-11-24T21:57:31ZengGrupo Aula MédicaFarmacia Hospitalaria1130-63432171-86952015-01-01393809110.7399/fh.2015.39.2.8218Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitisM. Galván-Banqueri0M. D. Vega-Coca1M. A. Castillo-Muñoz2C. Beltrán Calvo3T. Molina López4Andalusian Agency for Health Technology Assessment. Seville. SpainAndalusian Agency for Health Technology Assessment. Seville. SpainAndalusian Agency for Health Technology Assessment. Seville. Spain.Andalusian Agency for Health Technology Assessment. Seville. Spain.Andalusian Agency for Health Technology Assessment. Seville. Spain. Objective: To compare the relative efficacy of infliximab, adalimumab and golimumab through adjusted indirect treatment comparisons (ITCs). Methods: An exhaustive search was performed until October 2013. Databases consulted were MEDLINE, EMBASE, the Cochrane Library, the Centre for Reviews and Dissemination and the Web of Science. Randomized control trials (RCTs) comparing the efficacy of infliximab, adalimumab or golimumab versus placebo, in terms of clinical remission, clinical response and mucosal healing, were included. In the case that more than one RCT fulfilled the inclusion criteria for the same drug, a metanalysis was undertaken using a fixed effects model. ITCs were carried out using the method proposed by Bucher et al. Results: 6 RCTs published in 5 papers were included: 2 for infliximab (ACT 1 and ACT 2), 2 for adalimumab (ULTRA 1 y ULTRA 2) and 2 for golimumab (PURSUIT-SC y PURSUIT-M).In these RTCs, each biological agent was superior in efficacy to placebo. The results of the adjusted ITC are the following. In relation to the clinical remission, in the induction and maintenance period, there are no statistically significant differences between the three anti-TNF drugs. In relation to the clinical response and mucosal healing, in the induction period, there are statistically significant differences between infliximab and adalimumab. Conclusion: In view of the results obtained, infliximab, adalimumab and golimumab appear to be similarly effective therapeutic alternatives. Therefore, other considerations such as safety, tolerance and cost-effectiveness should be taken into account in order to select the most appropriate treatmenthttp://www.aulamedica.es/fh/pdf/8218.pdfAnti-TNFUlcerative colitisInfliximab; Adalimumab; Golimumab; Indirect treatment comparisons
collection DOAJ
language English
format Article
sources DOAJ
author M. Galván-Banqueri
M. D. Vega-Coca
M. A. Castillo-Muñoz
C. Beltrán Calvo
T. Molina López
spellingShingle M. Galván-Banqueri
M. D. Vega-Coca
M. A. Castillo-Muñoz
C. Beltrán Calvo
T. Molina López
Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis
Farmacia Hospitalaria
Anti-TNF
Ulcerative colitis
Infliximab; Adalimumab
; Golimumab
; Indirect treatment comparisons
author_facet M. Galván-Banqueri
M. D. Vega-Coca
M. A. Castillo-Muñoz
C. Beltrán Calvo
T. Molina López
author_sort M. Galván-Banqueri
title Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis
title_short Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis
title_full Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis
title_fullStr Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis
title_full_unstemmed Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis
title_sort indirect comparison for anti-tnf drugs in moderate to severe ulcerative colitis
publisher Grupo Aula Médica
series Farmacia Hospitalaria
issn 1130-6343
2171-8695
publishDate 2015-01-01
description Objective: To compare the relative efficacy of infliximab, adalimumab and golimumab through adjusted indirect treatment comparisons (ITCs). Methods: An exhaustive search was performed until October 2013. Databases consulted were MEDLINE, EMBASE, the Cochrane Library, the Centre for Reviews and Dissemination and the Web of Science. Randomized control trials (RCTs) comparing the efficacy of infliximab, adalimumab or golimumab versus placebo, in terms of clinical remission, clinical response and mucosal healing, were included. In the case that more than one RCT fulfilled the inclusion criteria for the same drug, a metanalysis was undertaken using a fixed effects model. ITCs were carried out using the method proposed by Bucher et al. Results: 6 RCTs published in 5 papers were included: 2 for infliximab (ACT 1 and ACT 2), 2 for adalimumab (ULTRA 1 y ULTRA 2) and 2 for golimumab (PURSUIT-SC y PURSUIT-M).In these RTCs, each biological agent was superior in efficacy to placebo. The results of the adjusted ITC are the following. In relation to the clinical remission, in the induction and maintenance period, there are no statistically significant differences between the three anti-TNF drugs. In relation to the clinical response and mucosal healing, in the induction period, there are statistically significant differences between infliximab and adalimumab. Conclusion: In view of the results obtained, infliximab, adalimumab and golimumab appear to be similarly effective therapeutic alternatives. Therefore, other considerations such as safety, tolerance and cost-effectiveness should be taken into account in order to select the most appropriate treatment
topic Anti-TNF
Ulcerative colitis
Infliximab; Adalimumab
; Golimumab
; Indirect treatment comparisons
url http://www.aulamedica.es/fh/pdf/8218.pdf
work_keys_str_mv AT mgalvanbanqueri indirectcomparisonforantitnfdrugsinmoderatetosevereulcerativecolitis
AT mdvegacoca indirectcomparisonforantitnfdrugsinmoderatetosevereulcerativecolitis
AT macastillomunoz indirectcomparisonforantitnfdrugsinmoderatetosevereulcerativecolitis
AT cbeltrancalvo indirectcomparisonforantitnfdrugsinmoderatetosevereulcerativecolitis
AT tmolinalopez indirectcomparisonforantitnfdrugsinmoderatetosevereulcerativecolitis
_version_ 1725855141090820096